[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"homeostasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:homeostasis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,37],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100637592","observational-study-of-electrical-impedance-tomography-for-non-invasive-assessment-of-cerebral-autoregulation-in-neurocritical-patients-100637592",false,"NCT07602114","Observational Study of Electrical Impedance Tomography for Non-Invasive Assessment of Cerebral Autoregulation in Neurocritical Patients","A Clinical Study of Non-Invasive Assessment of Cerebral Autoregulation Using Electrical Impedance Tomography","Inclusion Criteria:\n\n* Aged ≥18 years old\n* Diagnosed with acute intracerebral hemorrhage, subarachnoid hemorrhage or ischemic stroke, admitted to the Neurosurgical Intensive Care Unit\n* Receiving routine invasive monitoring of intracranial pressure (ICP) and mean arterial pressure (MAP)\n* Written informed consent obtained from the legally authorized representative\n\nExclusion Criteria:\n\n* Severe scalp damage, infection or skull defect affecting electrode placement\n* Craniotomy history with metal implants interfering with EIT signal acquisition Pregnancy\n* Terminal critical illness with estimated survival \\\u003C24 hours\n* Severe coagulation dysfunction or confirmed allergy to electrode materials\n* Unavailable for ≥2-hour continuous valid monitoring data collection","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This is a single-center, prospective, observational, self-controlled clinical study conducted at the Neurosurgical Intensive Care Unit of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study aims to evaluate whether non-invasive Electrical Impedance Tomography (EIT) can reliably assess cerebral blood flow autoregulation in neurocritically ill participants, by comparing EIT-derived parameters with the current gold-standard invasive index PRx.\n\nCerebral blood flow autoregulation helps maintain stable brain perfusion in critically ill neurological patients. Impaired autoregulation raises the risk of secondary brain injury. The current standard evaluation requires invasive intracranial pressure monitoring, which carries risks of infection, bleeding, and tissue damage. EIT is a non-invasive, radiation-free bedside monitoring technique that uses scalp electrodes to measure real-time changes related to cerebral blood flow, with no additional harm to participants.\n\nAdult participants admitted to the neurosurgical intensive care unit who require routine invasive intracranial pressure monitoring will be enrolled, with informed consent provided by legal guardians. All participants receive standard clinical care as prescribed by current medical guidelines; no extra experimental treatments, drugs, or invasive procedures are applied for this study.\n\nDuring the study, invasive monitoring data and non-invasive EIT brain monitoring data will be collected simultaneously. Researchers will analyze the correlation and consistency between EIT-derived parameters and the gold-standard index.\n\nThis study has received ethical approval from the Medical Ethics Committee of The First Affiliated Hospital, Air Force Military Medical University. All participant information is anonymized to protect privacy, and adverse events will be recorded and reported in accordance with regulatory requirements. The results are expected to support a safe, non-invasive monitoring method for cerebral blood flow autoregulation in neurocritical care.",[24],"Homeostasis","NOT_YET_RECRUITING","2026-05-24",{"date":28,"type":29},"2026-05-28","ACTUAL",{"date":31,"type":20},"2026-05-30",{"date":33,"type":20},"2028-05-30",{"name":35,"class":36},"Xijing Hospital","OTHER",{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":44,"sex":16,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100592111","probiotic-intervention-on-body-weight-100592111","NCT06989177","Probiotic Intervention on Body Weight","An Interventional Study Investigating the Effects of Probiotics on Body Weight and Metabolic Homeostasis","Inclusion Criteria:\n\n* Aged 20 to 50 years.\n* Normal-weight participants: 18.5 kg\u002Fm² ≤ Body Mass Index (BMI) \\\u003C 24 kg\u002Fm².\n* Overweight or obese participants:\n\nBMI ≥ 28 kg\u002Fm², or 24 kg\u002Fm² ≤ BMI \\\u003C 28 kg\u002Fm² and a clinical diagnosis meeting semaglutide treatment indications (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, cardiovascular disease, etc.).\n\n* Willingness to participate in this study and provide signed informed consent.\n\nExclusion Criteria:\n\n* Abnormal metabolic indicators (meeting any one of the following criteria is grounds for exclusion):\n\n  1\\. Normal weight (18.5 kg\u002Fm² ≤ BMI \\\u003C 24 kg\u002Fm²):\n  1. Waist circumference ≥ 90 cm for men or ≥ 85 cm for women.\n  2. Fasting glucose ≥ 6.1 mmol\u002FL or 2-hour postprandial glucose ≥ 7.8 mmol\u002FL, or a confirmed diagnosis of diabetes.\n  3. Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or currently under antihypertensive treatment.\n  4. Fasting triglycerides (TG) ≥ 1.7 mmol\u002FL; high-density lipoprotein cholesterol (HDL-C) \\\u003C 0.9 mmol\u002FL in men or \\\u003C 1.0 mmol\u002FL in women.\n\n  2\\. Overweight or obese (BMI ≥ 24 kg\u002Fm²):\n  1. Fasting plasma glucose \\> 11.1 mmol\u002FL or HbA1c \\> 9%, or previously diagnosed diabetes, or currently using insulin or any antidiabetic medication.\n  2. Blood pressure ≥ 160\u002F100 mmHg, or clinically diagnosed stage 2 or stage 3 (moderate or severe) hypertension, or currently under antihypertensive treatment.\n  3. Use of lipid-lowering drugs (e.g., fibrates, bile acid sequestrants, statins, PCSK9 inhibitors) within the past 3 months, or TG ≥ 5.7 mmol\u002FL, or LDL ≥ 4.9 mmol\u002FL.\n* Pregnancy or lactation.\n* Self-reported weight change of more than 5 kg within the 90 days prior to screening.\n* Use of antibiotics, antimicrobials, or anti-inflammatory\u002Fanalgesic salicylates (e.g., aspirin) within the 3 months prior to screening for 3 days or more.\n* Use of estrogen therapy or other hormonal medications within the past 6 months.\n* Use of GLP-1 receptor agonists or probiotics within the past 3 months.\n* Heavy alcohol consumption (females \\> 40 g\u002Fday, approximately 250 mL of huangjiu \\[yellow rice wine\\], or 1000 mL of beer, or 100 mL of liquor per day; males \\> 80 g\u002Fday).\n* Severe liver or kidney dysfunction (ALT, AST, or serum creatinine exceeding 3 times the upper limit of normal, UACR ≥ 30 mg\u002Fg, or eGFR \\\u003C 60 mL\u002Fmin).\n* Gastrointestinal diseases affecting digestion and absorption (e.g., severe diarrhea, severe constipation, severe inflammatory bowel disease, peptic ulcer, gallstones, cholecystitis).\n* Underwent surgery within the past year (excluding appendectomy or hernia repair).\n* Severe cardiovascular or cerebrovascular diseases (e.g., heart failure, myocardial infarction, stroke, acute myocarditis, severe arrhythmia, or receiving interventional therapy).\n* Presence of metallic implants such as a cardiac stent or pacemaker.\n* Cancer or having received radiation or chemotherapy within the past 5 years.\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia, or a personal history of hyperthyroidism or hypothyroidism.\n* Chronic or acute pancreatitis.\n* Positive hepatitis B surface antigen (HBsAg), active tuberculosis, HIV, or other infectious diseases.\n* Currently participating in another clinical study or having done so within the past 3 months.\n* Claustrophobia.\n* Any psychiatric disorder such as attention-deficit\u002Fhyperactivity disorder (ADHD), bipolar disorder, or epilepsy (including current use of antiepileptic medications), or use of antidepressant medications.\n* Inability to read, write, operate a smartphone, or perform daily activities independently.",true,"20 Years","50 Years",{"count":48,"type":20},140,"INTERVENTIONAL",[51],"NA","This study is a randomized controlled trial with 120 overweight or obese (body-mass index, BMI, ≥ 24 kg\u002Fm²) participants and 20 normal-weight participants. Twelve weeks of energy-restricted nutritional and lifestyle intervention with placebo, Lactobacillus paracasei LC-19 (LC-19), or semaglutide (a glucagon-like peptide-1 receptor agonist, GLP-1RA) will be randomly conducted in the overweight or obese participants. The primary goal is to clarify the roles of LC-19 and semaglutide in weight reduction and in improving energy, glucose, and lipid metabolism, while also comparing side effects, adverse events, and long-term outcomes such as weight regain between these two interventions. In addition, the study will explore key factors affecting intervention response to provide evidence for optimizing individualized intervention strategies.",[54,24,55,56],"Obesity","Weight Loss","Probiotic Intervention","RECRUITING","2026-03-16",{"date":60,"type":29},"2026-03-17",{"date":62,"type":29},"2025-06-10",{"date":64,"type":20},"2026-12-31",{"name":66,"class":67},"Chinese Academy of Sciences","OTHER_GOV",1]